Chris Loose, PhD

Chris Loose is the co-founder and CEO of Progentos Therapeutics, which aims to develop the first potentially restorative therapy for multiple sclerosis.

He has a distinguished career in the biotechnology sector, having co-founded two innovative Massachusetts Institute of Technology spin-off companies focused on developing platform technology to fulfill unmet clinical needs: Semprus BioSciences (acquired by Teleflex) and Frequency Therapeutics (IPO).

Chris served as chief scientific officer at Frequency Therapeutics from its founding in 2014 until July 2023. Before joining Frequency Therapeutics, he was the chief technology officer for Semprus BioSciences. During his tenure at Semprus, he led the technology team in developing medical products with surface modifications designed to reduce infection and clotting, achieving both FDA and European CE marketing clearance.

Prior to his entrepreneurial ventures, Chris worked as a chemical engineer at Merck Research Labs. In 2011, he was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation. His innovative contributions to technology have been recognized by his inclusion in the MIT Technology Review 35 Innovators Under 35 and the Boston Business Journal 40 Under 40.

Currently, Chris also serves as the executive director of Yale University’s Center for Biomedical and Interventional Technology and is an associate adjunct professor of urology in the Yale School of Medicine.

Chris holds a Ph.D. in chemical engineering from MIT, where he was a Hertz Fellow and studied under Robert Langer, Sc.D. He earned his B.S.E. in chemical engineering summa cum laude from Princeton University.